Therapy for Heavily Treated Multiple Myeloma Gets Fast Track Status from FDA
Cellectar Biosciences’ candidate CLR 131 received Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma…
Myeloma
Revlimid and Imnovid Triple Combos Approved in EU for Adults with Multiple Myeloma
The European Commission has approved two combination therapies based on Celgene‘s Revlimid (lenalidomide) and Imnovid (pomalidomide), added to Velcade (…
Takeda Oncology Launches Myeloma Patient and Caregiver Mentorship Support Program
Takeda Oncology has launched a mentorship program aimed at empowering and encouraging multiple myeloma patients and caregivers throughout their disease journey. Called…
Phase 3 Trial of Immune System-targeting Treatment for Advanced Multiple Myeloma Begins Dosing
A pivotal Phase 3 clinical trial has begun dosing participants to evaluate MorphoSys‘s investigational antibody, MOR202 (TJ202), in combination with Revlimid (lenalidomide)…
OncLive Poised to Induct 2019 Class of ‘Giants of Cancer Care’
OncLive, a digital resource platform for oncologists, will welcome 15 new members at its 7th Annual Giants of Cancer Care Winners Reception on May 30 in…
Allogene’s CAR T-cell Therapy Triggers Durable Anti-Tumor Response in Animal Model
ALLO-715, Allogene Therapeutics‘ donor-derived CAR T-cell therapy, can trigger a durable anti-tumor response in mice with multiple myeloma, and maintain its characteristics and…
Kyprolis Combo Shows Promise for Newly Diagnosed, Transplant-eligible Patients
A triple regimen composed of Kyprolis (carfilzomib), thalidomide, and dexamethasone, given before and after high-dose chemotherapy and autologous stem cell transplant, is safe…
bluebird bio Opens Manufacturing, Research Facility in Durham, N.C.
Bluebird bio has officially opened a facility in Durham, North Carolina, to make the lentiviral vector needed for its investigational gene and cell treatments, including…
Ninlaro Maintenance Therapy Prolongs and Boosts Treatment Benefits in Myeloma Patients, Study Says
Maintenance therapy with Ninlaro (ixazomib) can prolong and boost therapeutic responses from initial treatment in multiple myeloma patients who did not undergo an…
ChemioCare Developing New Lenalidomide Skin Patch
Aiming to improve lenalidomide‘s safety and efficacy, ChemioCare is setting up to develop a new treatment formulation delivered through a skin patch, maintaining an…
Recent Posts
- Treatment before surgery slows PDAC disease progression: Study
- Scientists discover tissue differences in brain cancer in children
- Elahere approved in EU as treatment for ovarian cancer
- Survival better with Blenrep combo than Darzalex for R/R myeloma
- Aucatzyl, a cell therapy, approved in US for adults with advanced B-ALL